CMS Releases CY 2015 ESRD PPS and DMEPOS Proposed Rule

by King & Spalding

On July 2, 2014, CMS released the CY 2015 End-Stage Renal Disease (ESRD) Prospective Payment System (PPS) and Durable Medical Equipment Prosthetics, Orthotics, and Supplies (DMEPOS) Proposed Rule. CMS estimates that the proposed changes would result in a 0.3 percent increase in total payments to all ESRD facilities in CY 2015 as compared with CY 2014, but that total payments to rural facilities would be expected to decrease by 0.5 percent under the proposals. The expected decrease in payments to rural ESRD facilities is the result of proposed changes to revise and rebase the ESRD bundled market basket. The Proposed Rule also includes proposed changes to the ESRD Quality Incentive Program for Payment Years (PYs) 2017 and 2018 and proposed changes to the DMEPOS competitive bidding payment methodology. Comments on the Proposed Rule must be received by 5:00 p.m. on Tuesday, September 2, 2014.

According to CMS estimates, freestanding ESRD facilities would see a roughly 0.3 percent payment increase, while payments to hospital-based ESRD facilities would increase approximately 0.5 percent overall. Urban ESRD facilities should expect a payment increase of roughly 0.4 percent under the Proposed Rule. Payments to rural facilities, on the other hand, would be expected to decrease by 0.5 percent, and ESRD facilities in Puerto Rico and the U.S. Virgin Islands would expect to see a decrease of 3.6 percent in total payments.

The estimated decrease in payments to rural ESRD facilities appears to be driven largely by an increase in the labor-related share value, which CMS proposes to increase from 41.737 percent to 50.673 percent. Because of the negative effect this proposed change would have on payments to rural facilities, CMS proposes to phase in its implementation, with 50 percent of payments in CY 2015 being based on the old labor-related share, and 50 percent on the new labor-related share. By CY 2016, 100 percent of payments would be based on the new labor-related share.

The proposed increase in the labor-related share, in turn, is a result of CMS's proposal to rebase and revise the ESRD bundled market basket. CMS proposes to rebase the market basket using CY 2012 data to more accurately track the input costs of ESRD providers under the recently fully-implemented ESRD bundled payment system. (The existing market basket is based on data from CY 2008.) Due to the decline in drug utilization during the 2008 to 2012 period, concurrently with implementation of the bundled payment system, the CY 2012 data reflects a higher compensation cost share (and lower pharmaceutical cost share) than was previously the case. In addition to this rebasing proposal, CMS also proposes to revise the market basket by (1) changing the price measures for pharmaceuticals and supplies to more specific measures, and (2) updating the price measure for compensation costs to better reflect the occupational mix in the ESRD setting. Table 8 of the Proposed Rule (on page 67 of the display copy), displays the comparison between the CY 2008-based market basket and the proposed rebased CY 2012-based market basket.

CMS proposes to raise the ESRD outlier fixed-dollar loss amount for pediatric patients from $54.01 to $56.30, and increase the Medicare Allowable Payment (MAP) amount from $37.29 to $40.05. For adult patients, CMS proposes to lower the fixed-dollar loss amount from $98.67 to $85.24, and increase the MAP amount from $51.97 to $52.61.

The Proposed Rule also includes a number of revisions to the PY 2017 and PY 2018 ESRD Quality Incentive Program. For PY 2017, CMS proposes eight clinical measures and three reporting measures. With respect to the proposed clinical measures, one is new (the proposed Standardized Readmission Ratio measure), one has been revised (the National Healthcare Safety Network (NHSN) Bloodstream Infection in Hemodialysis Outpatients measure), and CMS proposes to remove one "topped out" measure (the Hemoglobin Greater than 12 measure). As for the reporting measures, CMS proposes that facilities will no longer be able to attest that they only had a single qualifying case to avoid being scored on the measure.

For PY 2018, CMS proposes eleven clinical measures and five reporting measures. CMS proposes to group the clinical measures for PY 2018 into three subdomains: (i) Safety, (ii) Patient and Family Engagement/Care Coordination, and (iii) Clinical Care. Each subdomain will comprise 20 percent, 30 percent, and 50 percent, respectively, of the total Clinical Measure Domain score. Among the proposed revisions to the reporting measures in PY 2018 are three new measures: (i) Pain Assessment and Follow-Up, (ii) Clinical Depression Screening and Follow-Up, and (iii) NHSN Healthcare Personnel Influenza Vaccination.

The Proposed Rule also includes a number of proposed changes to the DMEPOS payment methodology for CY 2015. Notably, CMS has proposed a methodology for using data gathered from the DMEPOS Competitive Bidding Program (CBP) to adjust the fee schedule prices for DME in regions of the country with no CBPs. For certain areas under the CBP, CMS proposes to phase in a system of monthly bundled payments (in replace of capped rental policies) to cover equipment costs, supplies, accessories, maintenance, and repair of certain equipment and devices furnished under the CBP, including enteral nutrition, oxygen, standard manual and power wheelchairs, hospital beds, continuous positive airway pressure devices, and respiratory assist devices. CMS also proposes an exception to the change of ownership rules that would permit a competitive bidding contract supplier to sell a distinct company that furnishes a specific product category or competitive bidding area.

The Proposed Rule is scheduled for publication in the July 11, 2014 Federal Register. The Proposed Rule is available here. The CMS Fact Sheet on the proposed payment update provisions included in the CY 2015 ESRD PPS Proposed Rule is available here. The Fact Sheet on the proposed quality measure updates is available here.

Reporter, Susan Banks, Washington, D.C., +1 202 626 2953,


Written by:

King & Spalding

King & Spalding on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.